Operating Margin
Seagen Inc

-32.6%
Current
-16%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-32.6%
=
Operating Profit
-750.5m
/
Revenue
2.3B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Seagen Inc
F:SGT
39.3B EUR
-33%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.3B USD
33%
US
Amgen Inc
NASDAQ:AMGN
175.8B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
147.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD
28%
AU
CSL Ltd
ASX:CSL
84B AUD
26%
NL
argenx SE
XBRU:ARGX
45.1B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD
8%
No Stocks Found

Seagen Inc
Glance View

Seagen Inc., nestled in the vibrant Pacific Northwest, has carved out a formidable niche in the biotech arena with its relentless focus on oncology advancements. Born in 1997 as Seattle Genetics, this company has developed a reputation for its pioneering work in antibody-drug conjugates (ADCs). These innovative therapies are designed to deliver potent anti-cancer agents directly to tumor cells, minimizing damage to healthy tissues. Its flagship product, Adcetris, targets various Hodgkin’s lymphomas and has been instrumental in redefining treatment paradigms. This high-caliber development is not just a product of cutting-edge science, but of Seagen's strategic approach to partnerships and collaborations with other pharmaceutical giants, amplifying its research and market reach. Revenue for Seagen doesn't merely stem from its internal product pipeline; it also thrives on strategic alliances and licensing agreements. By engaging in collaborations with leading firms like Pfizer and Takeda, Seagen extends its influence beyond its direct sales, earning substantial sums from milestone payments and royalties as partners bring drugs to market. Furthermore, its business model is deeply entwined with a global vision, where navigating regulatory landscapes across different countries not only expands its market share but also its scientific influence. Seagen’s business strategy is a testament to how innovation in drug delivery mechanisms and thoughtful alliances can coalesce into a formidable presence in the biopharmaceutical industry, fueling both growth and a greater mission in the fight against cancer.

SGT Intrinsic Value
Not Available
S
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-32.6%
=
Operating Profit
-750.5m
/
Revenue
2.3B
What is the Operating Margin of Seagen Inc?

Based on Seagen Inc's most recent financial statements, the company has Operating Margin of -32.6%.

Back to Top